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Panzyga® is a new glycine-formulated immune globulin intravenous 10% liquid for the treatment of
patients suffering from immunodeﬁciencies and autoimmune diseases.
Panzyga® is a high purity, native and functional IgG product with an IgG subclass distribution
equivalent to normal plasma. The levels of hemagglutinins and accompanying plasma proteins (including
IgA and IgM) are low. Potential procoagulant activity is not detectable. Functional activity of the IgG was
demonstrated by opsonophagocytosis and receptor binding assays. Dynamic light scattering measure-
ments and ﬂuorescent dye binding were used to characterize the integrity of the IgG molecule.
Panzyga® is stable under refrigerated storage for at least two years regarding all assessed physico-
chemical and functional parameters; it can also be stored at room temperature for at least twelve months
within its total shelf-life.
© 2016 The Author(s). Published by Elsevier Ltd on behalf of International Alliance for Biological
Standardization. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
Intravenously administered immune globulin (IVIG) is used to
treat immunodeﬁciencies and autoimmune diseases, a therapy
which may be lifelong [1e3]. The worldwide immune globulin
demand has grown signiﬁcantly during the last two decades and
called for improved production processes to assure the supply of
sufﬁcient, safe, and efﬁcacious IVIG products for patients world-
wide. These preparations consist of immune globulin G (IgG) iso-
lated from pooled human plasma, employing manufacturing
processes able to maintain the physicochemical and functional
integrity of the IgG molecule, as well as product stability, and to
ensure safety including minimizing the risk for pathogen trans-
mission [4]. The long history of immune globulin preparations with
lyophilized products lead to the development of liquid formula-
tions, targeting a more convenient use [5]. The purity of the more
recent preparations has increased as well. However, concentratedtika Produktionsgesellschaft
(C. Mersich).
er Ltd on behalf of International Al
y-nc-nd/4.0/).
C, et al., Biochemical charac
.org/10.1016/j.biologicals.2016IgG solutions of 10% and beyond require appropriate formulations
for liquid storage to preserve the characteristics without hampering
their quality such as increasing protein aggregation [6] and po-
tential reduction of functional properties [7].
Panzyga® presents as a state-of-the-art high purity, safeguarded,
and native immune globulin intravenous 10% liquid. The efﬁcacy of
Panzyga® was assessed in phase III clinical trials in patients with
primary immunodeﬁciency disorders and adults with primary
immune thrombocytopenia (unpublished data).
The manufacturing process of Panzyga® comprises two dedi-
cated virus reduction steps supported by a validated ion-exchange
chromatography step (unpublished data). Likewise, two
manufacturing steps reveal high prion removal capacities,
demonstrated in laboratory validation studies using spikes of in-
fectious prion protein (unpublished data). The process was
designed and implemented to assure a robust large-scale
manufacturing and to consistently provide a product with high
yield and conﬁrmed quality.
The physicochemical, functional, and safety in vitro character-
istics were determined from six consecutive, recently produced,
Panzyga® batches. Altogether, 19 batches were used to study the
long-term stability of Panzyga®.liance for Biological Standardization. This is an open access article under the CC BY-
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Table 2
Functional characteristics of Panzyga® (n ¼ 6 batches).
Parameter Units Mean ± SD
Fc function % 100 ± 0
Fcg receptor binding % relative to BRP 109.4 ± 7.1
Opsonophagocytosis % relative to BRP 119.2 ± 6.6
BRP Human immune globulin biological reference preparation Y0001512 batch 1.
Table 3
Antibody titers for pathogens Panzyga® (n ¼ 6 batches).
Antibody speciﬁcity Units Mean ± SD
Hepatitis A virus IU/mL 31.7 ± 7.1
Hepatitis B virus surface antigen IU/mg of IgG 87.0 ± 19.5
Parvovirus B19 IU/mL 355 ± 19
Poliovirus relative to NIH176 0.94 ± 0.29
Measles virus relative to NIH176 0.58 ± 0.15
Diphtheria toxin U/mL 12.9 ± 2.0
Haemophilus inﬂuenzae type b mg/mL 32.5 ± 4.3
Rubella virus IU/mL 600 ± 91.9
Streptococcus pneumoniae mg/mL 646 ± 126
Streptolysin O IU/mL 1,710 ± 216
Tetanus toxin IU/mL 27.7 ± 2.9
Varicella zoster virus mIU/mL 10,700 ± 1137
Table 4
Residual coagulation factors in Panzyga® (n ¼ 6 batches) and coagulation assays.
Parameter Units Mean
TGA: FXIa-like activity mU/mL <0.25
NATEM: clotting time s >1500
FII IU/mL <0.016
FVII IU/mL <0.015
C. Mersich et al. / Biologicals xxx (2016) 1e622. Materials and methods
2.1. Manufacturing process
Panzyga® is produced from pooled human plasma, where single
donations are screened for absence of viral markers by sensitive,
state-of-the-art methods. The manufacturing process includes ion-
exchange chromatography, solvent/detergent (S/D) treatment, and
subsequent S/D removal. After 20 nm virus removal ﬁltration and
concentration the product is formulated and ﬁlled in 10, 25, 50,100,
200, and 300 mL vials, respectively.
2.2. Biochemical investigations
Six consecutive Panzyga® batches were analyzed.
Total protein and IgG-related parameters: Protein concentra-
tions were determined by a Biuret method. IgG and IgG subclass
concentrations were quantiﬁed by respective nephelometric
methods (Siemens System; Erlangen, Germany). Molecular size
distribution of monomers, dimers, polymers and fragments were
determined according to European Pharmacopeia (EP) monograph
8.0 [8] 0918, general method 2.2.29 and 2.2.46, by size exclusion
chromatography (SEC). Anticomplementary activity (ACA) [9] was
measured according to EP 8.0 [8] 2.6.17. Hemagglutinins: anti-A and
anti-B titers (direct method) were tested according to EP 8.0 [8]
2.6.20 method B. Anti-D titers (direct method) were determined
according to EP 8.0 [8] 2.6.26.
Accompanying plasma proteins: IgA, IgM, albumin, transferrin,
and ﬁbrinogen were quantiﬁed by in-house enzyme-linked
immunosorbent assay (ELISA) methods. Proteolytic activity was
assessed using the chromogenic substrate CS-05(88) (HyphenTable 1
Product characteristics of Panzyga® (n ¼ 6 batches).
Parameter Units Mean ± SD
Total protein mg/mL 105 ± 2.5
IgG mg/mL 105 ± 1.7
IgG molecular size distributiona
Monomer þ dimer % 99.7 ± 0.08
Polymer % 0.3 ± 0.08
Fragments % <0.5
IgG subclass distributionb
IgG1 % 66.0 ± 2.98
IgG2 % 27.2 ± 2.98
IgG3 % 3.0 ± 0.22
IgG4 % 3.8 ± 0.26
Anticomplementary activity CH50/mg IgG 0.62 ± 0.10
Accompanying plasma proteins
Anti-A hemagglutinin Titer 8e16
Anti-B hemagglutinin Titer 4e8
Anti-D hemagglutinin Titer <2
IgA mg/mL 41.7 ± 11.0
IgM mg/mL 1.0 ± 0.09
PKA IU/mL <2.0
PKA blank IU/mL <2.0
Proteolytic activity U/L <3.0
Albumin mg/mL 1.72 ± 1.55
Transferrin mg/mL 0.29 ± 0.11
Fibrinogen mg/mL 0.14 ± 0.16
Physicochemical parameters
pH 4.8 ± 0.05
Osmolality mOsmol/kg 276.3 ± 3.3
Glycine mg/mL 17.0 ± 0.29
Viscosity (20 C) mPa*s 3.35 ± 0.15
Density (20 C) kg/m3 1034 ± 1.3
CH50 half-maximal complement hemolytic activity.
PKA prekallikrein activator.
a Expressed as a percentage of the total chromatogram area.
b Expressed as a percentage of total IgG.
FVIIa mIU/mL <8.4
FIX IU/mL <0.018
FIXa mIU/mL <4.0
FX IU/mL <0.016
FXI IU/mL <0.015
FXIa mU/mL <1.0
FXII IU/mL <0.014
TGA thrombin generation assay.
NATEM non-activated thromboelastometry.
Please cite this article in press as: Mersich C, et al., Biochemical charac
(Panzyga®), Biologicals (2016), http://dx.doi.org/10.1016/j.biologicals.2016Biomed, Neuville-sur-Oise, France). Prekallikrein activator (PKA)
and PKA blank were measured according to EP [8] 2.6.15 using the
chromogenic substrate S-2302™ (Chromogenix; Instrumentation
Laboratory, Bedford, MA, USA).
Physicochemical parameters: Osmolality was determined ac-
cording to EP 8.0 [8] 2.2.35. Viscosity was measured with a falling-
sphere viscometer (AMVn; Anton Paar GmbH, Graz, Austria).
Density was determined with a DMA 4500 M instrument (Anton
Paar GmbH, Graz, Austria). Glycinewas quantiﬁed after pre-column
derivatization according to EP 8.0 [8] 2.2.56 by a reversed phase
HPLC method.
Dynamic light scattering (DLS) measurements were performed
using a Malvern Zetasizer Nano-ZS (Malvern Instruments Ltd,
Malvern, UK). Results are provided as intensity-based size distri-
bution proﬁle, as well as using polydispersity index (PDI) and Z-
average (intensity-weighted mean diameter derived from cumu-
lants analysis) [10]. The PDI value describes the broadness of the
size distribution, ranging from 0 (theoretical) for a perfectly mono-
disperse sample to 1 for a sample with a very broad size distribu-
tion containing multiple particle sizes. Samples were measured
undiluted as well as in a 1:5 dilution using 154 mM NaCl.
Fluorescent dye binding with Nile Red (NRB): protein solutions
were diluted to a concentration of 10 mg/mL in MES buffer
(100 mM 2-(N-morpholino) ethanesulfonic acid, 1 mM ethyleneterization and stability of immune globulin intravenous 10% liquid
.10.003
(a)
(b)
Hydrodynamic Radius [nm]
0.1 1 10 100 1000 10000
]
%[
ytisnetnIthgiL
derettac
S
0
2
4
6
8
10
12
14
16
Batch 1
Batch 2
Batch 3
Batch 4
Batch 5
Batch 6
Hydrodynamic Radius [nm]
0.1 1 10 100 1000 10000
]
%[
ytisnetnIthgiL
derettac
S
0
5
10
15
20
25
Batch 1
Batch 2
Batch 3
Batch 4
Batch 5
Batch 6
Fig. 1. Dynamic light scattering proﬁles for Panzyga® (overlay of n ¼ 6 batches). (a)
without dilution; (b) diluted 1:5 in 154 mM sodium chloride solution.
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Fig. 2. Nile Red binding results of Panzyga® (n ¼ 6 batches) in comparison to BRP (human
rescence intensity (relative ﬂuorescence units, RFU) and wavelengths at peak maximum (n
intensity and no shift of the wavelength at the peak maximum compared to the BRP IgG s
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(Panzyga®), Biologicals (2016), http://dx.doi.org/10.1016/j.biologicals.2016glycol-bis(2-aminoethylether)-N,N,N0,N0-tetraacetic actid, 1 mM
MgCl2, pH 6.9). 50 mL of each sample was pipetted into a quartz
cuvette and a blank emission spectrum was read between 570 and
720 nm in a Spectral Fluorescence Photometer (RF 5301 PC, Shi-
madzu, Duisburg, Germany) with excitation wavelength set to
550 nm. 4 mL of a 0.25 mM solution of Nile Red in DMSOwas added;
the samples were mixed thoroughly and incubated at room tem-
perature. After 30 s, again an emission spectrumwas read with the
same settings as the blank spectrum, which was subtracted from
the spectrum after addition of Nile Red. The ﬂuorescence intensity
at the peak maximum and the wavelength of the peak maximum
were used to judge the integrity of the proteins.
Residual coagulation factors: Coagulation factors FII, FVII, and FX
were quantiﬁed based on the prothrombin time (PT) test. Factors
IX, FXI and FXII were assessed using a modiﬁed activated partial
thromboplastin time (aPTT) method. Activated Factor VII (FVIIa)
was determined using the Staclot® VIIa-rTF assay kit (Diagnostica
Stago SAS, Asnieres sur Seine, France). Clotting activities were
assessed using the ACL System (Werfen, Kirchheim, Germany).
Factor IXa activity was determined with the BIOPHEN® Factor IXa
Kit (Hyphen Biomed, Neuville-sur-Oise, France), FXIa with the Rox
Factor XIa test kit (Rossix, M€olndal, Sweden).
Thrombin generation assay (TGA): Thrombin generation in FXI
deﬁcient plasma was measured using the Technothrombin® assay
(Technoclone GmbH, Vienna, Austria) and internal calibration with
FXIa (National Institute for Biological Standards and Control
(NIBSC) reference reagent 11/236). The response was evaluated as
FXIa-like activity. Thromboelastography: clotting time in recalciﬁed
FXI-deﬁcient plasma (non-activated thromboelastometry; NATEM)
was determined using a ROTEG® 05 instrument (TEM Innovations
GmbH, Munich, Germany).
Antibody titers: Parvo B19 titers were determined by ELISA
methods (Mikrogen, Neuried, Germany), hepatitis B surface antigen
and hepatitis A titers by chemiluminescence immune assay (CLIA)
methods (Access; Beckman Coulter Inc., Brea, CA, USA). Polio and
measles titers were measured by in vitro neutralization tests,
antistreptolysin O titers by nephelometric methods (Labor Enders,
Stuttgart, Germany). Diphtheria titers were tested by in vivo
neutralization (Medical University Vienna, Department für Bio-
medizinische Forschung, Abteilung Labortierkunde und Genetik,
Himberg, Austria). Tetanus-antitoxin, Haemophilus inﬂuenzae typebatch 
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Fig. 3. Change in (a) IgG content, (b) polymers, (c) monomers/dimers; and representative antibody titers: (d) anti-hepatitis A virus antibodies (HAV Ab), (e) anti-parvovirus B19
antibodies (Parvo Ab), (f) diphtheria antitoxin, and (g) anti-poliovirus type 1 antibodies over time during storage of Panzyga® at 5 C ± 3 C (n ¼ 19 batches). The calculated
arithmetic mean of all batches at time point zero (t0 results) is used as reference value (0.0). For each of the following time points (tx) the absolute change of the arithmetic mean of
all batches compared to time point zero (tx-t0) is shown. The error bar at time point zero indicates the standard deviation of the initial values, for all other time points it indicates the
standard deviation of the absolute changes.
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C. Mersich et al. / Biologicals xxx (2016) 1e6 5b, Varicella Zoster virus, Rubella virus and Streptococcus pneumo-
niae (serotypes 1e5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C,
19F, 20, 22F, 23F, 33F) were quantiﬁed by ELISA methods (Labor
Enders, Stuttgart, Germany).
Functional parameters: Fc function was determined according
to EP [8] 2.7.9. Binding to cellular Fcg receptor was determined
using ﬂuorescence-activated cell sorting (FACS) (Glycotope GmbH,
Berlin, Germany). Opsonophagocytosis capacity was assessed by
means of a neutrophil-based assay investigating the opsonic ac-
tivity of IgG for the bacterial strain S. pneumoniae (Serotype 6B,
DSMZ 11867) using FACS (Glycotope GmbH, Berlin, Germany). Re-
sults of both assays were expressed in relation to the Human Im-
mune Globulin Biological Reference Preparation (BRP) Y0001512
batch 1; supplied by the European Directory for the Quality of
Medicines (EDQM).
2.3. Stability assessment
The stability of Panzyga® was assessed in accordance with cur-
rent guidelines of the International Conference on Harmonization
[11,12]. The stability of 19 batches was evaluated for 24 months
under long-term storage conditions (þ5 C ± 3 C andþ25 C ± 2 C
with 60% ± 5% relative humidity, each inverted in the dark).
Stability parameters, tested at each time point, were: IgG con-
centration, molecular size distribution (polymers, monomers and
dimers, fragments), hepatitis A virus antibody, parvovirus B19
antibody, antibodies against measles, diphtheria, and poliovirus.
For IgG content, monomers and dimers, polymers, anti-
parvovirus B19 antibodies, anti-hepatitis A virus antibodies, diph-
theria antitoxin, and anti-poliovirus type 1 antibodies, the arith-
metic means of results from all batches at initial testing (time point
zero; t0) and the corresponding standard deviations were calcu-
lated. In the graphical representations, these values were set to
zero. For all following time points, the differences between initial
values and actual time point values were calculated. From these
results, a mean and corresponding standard deviation was calcu-
lated and used in the graphical representation.
To statistically evaluate any difference between the mean score
of the initial testing and each of the subsequent time points, a two
sample t-test (p < 0.05) and a preliminary test for the equality of
variances (p < 0.05) were performed for the above mentioned
parameters.
3. Results
3.1. Biochemical data
Results of the biochemical, biological and functional parameters
analyzed are summarized in Tables 1e4. Parameters tested from six
consecutive batches are presented as mean values ± standard
deviations.
Panzyga® is a glycine-formulated immune globulin intravenous
10% liquid with an average osmolality of 276.3 mOsmol/kg, a pH of
4.8, and a viscosity at 20 C of 3.35 mPa*s. Panzyga® revealed an
IgG monomer and dimer content of 99.7% on average measured by
size exclusion chromatography, and a corresponding polymer
portion as low as 0.3%, while fragments were not detectable
(below limit of quantiﬁcation of 0.5%). In addition, intensity dis-
tributions obtained from DLS measurements (Fig. 1), showed
reproducible results from batch to batch, conﬁrming a very
reproducible process leading to consistent molecular size distri-
butions. It has to be considered, that larger molecular mass ag-
gregates scatter light in a much higher, non-proportional intensity
[10]. For undiluted Panzyga® samples, bimodal intensity-based
size distributions were recorded with a mean PDI ofPlease cite this article in press as: Mersich C, et al., Biochemical charac
(Panzyga®), Biologicals (2016), http://dx.doi.org/10.1016/j.biologicals.20160.254 ± 0.006 SD and a z-average of 2.16 nm ± 0.065 SD (Fig. 1a).
Due to multiple scattering effects at high protein concentrations
[13], such as 10%, z-average values cannot be reliably calculated in
undiluted samples [10,14]. Therefore, sample dilution as per-
formed for Panzyga® batches is necessary to obtain reliable size
information. After a 1:5 dilution with 0.9% NaCl, unimodal distri-
butions were detected with a mean PDI of 0.048 ± 0.007 SD and a
mean Z-average of 5.99 nm ± 0.023 SD (Fig. 1b). This behavior is
expected, since highly concentrated protein solutions tend to
show self-association due to electrostatic interactions, which is
reversible upon dilution [13]. This is conﬁrmed by the very sharp
and symmetric unimodal size distributions and low PDI values
found in the 1:5 diluted Panzyga® batches, which also mimics
dilution after administration.
Nile Red binding is used to demonstrate the integrity of IgG
molecules [15,16]. During protein denaturation processes, hydro-
phobic domains become more exposed towards their environment.
These exposed domains are then more accessible for the Nile Red
ﬂuorochrome. Hence, increased ﬂuorescence intensity and shifting
towards a shorter emissionwavelength at peak maximum, indicate
protein unfolding and potential denaturation processes. All six
consecutive batches showed very low ﬂuorescence intensity
without a shift of the wavelength at the peak maximum compared
to the BRP IgG standard (Fig. 2). These results underline the nativity
of the IgGmolecule in Panzyga® revealing consistently very lowdye
binding.
The low anticomplementary activity with a mean of 0.62 CH50/
mg IgG was in line with the integrity of Panzyga® as well as very
low levels of complement ﬁxing polymers (Table 1). Biological
parameters, such as Fc function, Fcg receptor binding and opso-
nophagocytosis conﬁrmed the nativity and full functionality of
Panzyga® (Table 2).
Panzyga® comprised a subclass distribution of IgG1 (66%), IgG2
(27%), IgG3 (3%) and IgG4 (4%) (Table 1), which is in accordance
with the subclass distribution typical for human plasma [17].
Accompanying plasma proteins, such as IgA, were solely present at
low concentrations (Table 1). Hemagglutinins were present at low
titers: anti-A ranged from 8 to 16, and anti-B from4 to 8. Anti-Dwas
below the limit of quantiﬁcation. A broad spectrum of antibodies,
reactive to common bacterial and viral pathogens or respective
antigens/toxins, was conﬁrmed to be present at protective levels
(Table 3), which is in particular of utmost importance for the
treatment of primary immunodeﬁciency patients.
Proteolytic activity and PKA were below their respective limits
of quantiﬁcation. No procoagulant activity was detectable in the
ﬁnal product as conﬁrmed by NATEM and TGA (FXIa-like activity).
Accordingly, all measured coagulation factors were below the
respective LOQs of the assays (Table 4).
3.2. Stability data
Panzyga® was stable during storage at 5 C for at least 24
months. There was no statistically signiﬁcant decrease in IgG con-
tent (Fig. 3a) and titers of antibodies against hepatitis A virus
(Fig. 3d), diphtheria antitoxin (Fig. 3f) and anti-poliovirus type 1
antibodies (Fig. 3g) throughout 24 months. Only a slight decrease
was observed for anti-parvovirus B19 (Fig. 3e).
The percentage of polymers increased only slightly by approx-
imately 0.2% over 24 months (Fig. 3b), and remained clearly below
1.0%. The percentage of monomers/dimers decreased correspond-
ingly by approximately 0.3% (Fig. 3c).
At 25 C (60% relative humidity) Panzyga® remained within the
predeﬁned speciﬁcations e as deﬁned by EP, US Pharmacopeia
(USP), and internal limits e throughout a storage period of twelve
months (data not shown).terization and stability of immune globulin intravenous 10% liquid
.10.003
C. Mersich et al. / Biologicals xxx (2016) 1e664. Discussion
Efﬁcacy, safety and tolerability are important features for an
IVIG [3]. The high purity of the product is a prerequisite tominimize
co-administration of accompanying plasma proteins, potentially
impairing the tolerability of the product. First plasma-derived IVIG
preparations were provided as lyophilized concentrates, whereas
newgeneration liquid products are more convenient, save time and
eliminate the risk of incomplete or wrong reconstitution [18].
Altogether they offer potential pharmacoeconomic beneﬁts and
potential reduction of adverse events [19]. Quality requirements for
plasma-derived proteins are extensive and regulated for IVIG in the
European Pharmacopoeia (EP) monograph 0918 and the US Phar-
macopoeia, as well as in other regulatory documents. These re-
quirements comprise protein concentration, purity (e.g. IgA),
adverse reaction relevant protein impurities (PKA), speciﬁc adverse
reaction-associated activity (hemagglutinin activity, anti-
complementary activity, FXIa-like activity), indicators of function-
ality of the IgG molecule (Fc function) and bioburden (pyrogens,
endotoxins, sterility). The manufacturing process must be robust
enough to remove unwanted compounds, which may cause
adverse events, but e on the other hand e gentle enough to assure
the integrity and nativity of the IgG molecule [3,20]. It has to be
shown during process validation, that each production step main-
tains the integrity of the immunoglobulin molecule. Additional
methods not stipulated by the pharmacopoeias, such as dynamic
light scattering or Fcg receptor binding can be used to investigate
the integrity of IgG. Maintenance of subclass distribution during
manufacture is also important and should be optimized and
monitored. Process time and manufacturing conditions are
important parameters impacting the functional properties of IgG,
and a high yield as a measure for the optimal use of the precious
source - human plasma. Additionally, a 10% liquid IVIG is expected
to be stable for a reasonable period, even at elevated temperatures,
allowing for a convenient use.
Panzyga® was developed to meet these expectations for an
immune globulin intravenous 10% liquid.
At high purity, Panzyga® revealed full physicochemical and
functional integrity of plasma derived IgG. None or very low IgG
polymerization or fragmentation reﬂect the gentle process and
integrity and stability of the product, which was demonstrated by
several methods such as SEC and particularly sensitive DLS and
NRB. The results are in line with fully retained functional properties
such as Fc function and Fcg receptor binding. Low anti-
complementary activity (ACA) values conﬁrm that complement is
not consumed and activated. Particularly important for immuno-
deﬁcient patients, opsonophagocytosis reﬂects the composite ef-
fect of antigen binding via the functional F(ab) part of the speciﬁc
IgG to its target pathogen, while the Fc structure associates with
cellular receptors ﬁnally resulting in phagocytosis. These complex
interactions as demonstrated in cell-based in vitro assays are efﬁ-
ciently mediated by Panzyga®, exemplary presented for one clini-
cally important pathogen. Antibodies against pathogens or
compounds/toxins thereof were shown to be present in expected
and clinically relevant titers or concentrations, in accordance with
the guidelines. In addition to the full functionality of the IgG
molecule in Panzyga®, its manufacturing process was developed to
provide an extensive safety margin for a potential pathogen
transmission (unpublished data) and product speciﬁc characteris-
tics such as low hemagglutinin content, very low polymer content
and the absence of detectable PKA and procoagulant factors.
Panzyga® presents as a glycine-formulated immune globulin
intravenous 10% liquid with low viscosity, ensuing convenient
treatment of patients. Panzyga® is stable at 5 C ± 3 C for 2 years,
demonstrated by the assessment of physicochemical, biological/Please cite this article in press as: Mersich C, et al., Biochemical charac
(Panzyga®), Biologicals (2016), http://dx.doi.org/10.1016/j.biologicals.2016functional and safety related parameters. No signiﬁcant reductions
of investigated pathogen titers were observed. At 25 C ± 2 C
(60% ± 5% relative humidity), stability for at least twelve months
was veriﬁed.
Panzyga® was successfully investigated in two clinical phase III
studies in primary immune deﬁciencies and adults with primary
immune thrombocytopenia. Panzyga® e as a novel immune glob-
ulin intravenous 10% liquid e was shown to be both safe and efﬁ-
cacious in the treatment of these patients.Acknowledgements
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